NCT04111913View on ClinicalTrials.gov

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2022

Conditions
Unresectable Stage III Non-small Cell Lung Cancer
Interventions
DRUG

Anlotinib Hydrochloride

anlotinib once daily on days 1-14 of 21days cycle.

Trial Locations (1)

Unknown

RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Nanfang Hospital, Southern Medical University

OTHER